Wegovy®

Wegovy® (semaglutide) activates GLP-1 receptors to enhance insulin secretion, slow gastric emptying, and decrease appetite. It’s an established therapy for chronic weight management when paired with lifestyle modifications such as diet and exercise.

Eligibility:
Patients with a BMI of 30+, or 27+ with a weight-related condition (like type 2 diabetes, hypertension, or high cholesterol), may qualify. Providers may also consider patients with a BMI above 25 based on overall health and medical background.

Provider Review:
A licensed provider reviews each intake asynchronously — meaning no live doctor visit is required. They may request additional information to ensure safety and suitability, and will manage dosage adjustments to balance effectiveness and tolerability.

Process:

1. Submit your secure online intake form.
2. A licensed provider reviews your information (typically within 24 hours).
3. Once approved, medication is dispensed and shipped directly to you.

Expectations:

• Weeks 1–4: Appetite reduction and improved portion control are common.
• Weeks 8–12: Noticeable changes in body weight and metabolic function.
• 6 months and beyond: Sustained progress under provider guidance and continued monitoring.

Pricing is determined after provider evaluation and eligibility confirmation. Final costs depend on dosage, dispensing pharmacy, and treatment duration.